Analysis of genetic alterations by massive sequencing of primary tumor biopsies that were successfully engrafted (Table 3) identified the oncogenic KRAS mutation p.G12C in ADC samples LF05, LF09, and LF15, associating these mutations with successful PDX engraftment and aggressive disease. The gene discussed is KRAS; the disease is neoplasm.